Halozyme heads toward Phase III; Roche closes $1.2B Foundation Medicine deal;

@FierceBiotech: ICYMI: Nabriva preps for PhIII antibiotic trial with a $120M VC commitment. Story | Follow @FierceBiotech

@JohnCFierce: Alzheimer's startup Alzheon bags $10M and beats a path to Phase III. Article | Follow @JohnCFierce

@DamianFierce: ICYMI: Life sciences entrepreneurs, here is my gift to you: The Biotech Name Generator | Follow @DamianFierce

> Halozyme ($HALO) is back on track for a Phase III trial on its lead pancreatic cancer treatment, detailing its plans to the FDA after the agency lifted a hold on the drug's development. More

> Roche ($RHHBY) wrapped up its deal to take a $1.2 billion stake in Foundation Medicine ($FMI), planning to hand over $150 million over 5 years in a broad R&D collaboration. News

> FierceMedicalDevices takes a look at the world's top med tech companies by 2014 revenue. Report

Medical Device News

@FierceMedDev: FDA approves breath test for stomach disorder, highlights its ease of use over standard of care. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Alere earns FDA clearance for rapid diagnostic of Strep A. FierceDiagnostics story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: AdverseEvents: Analysis of side-effect reports turns up troubling safety signals for Novartis, Eisai drugs. Article | Follow @EmilyWFierce

> FDA recalls fall more than 50% in Q1 2015 after reaching record high in 2014. More

> Study: False alarms of breast cancer costing U.S. $4B a year. Story

> Medtronic debuts European study of its atrial fibrillation device. Article

Pharma News

@FiercePharma: ICYMI from FiercePharmaManufacturing: UAE drug distributor building a $20M plant in Dubai. Report | Follow @FiercePharma

@EricPFierce: Hospira has now received FDA warning letters for plants on 4 of 7 continents. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Shire could use boost from adult ADHD med to hit $10B goal. Report | Follow @CarlyHFierce

> Watch out for a two-front hep C price war when Merck's combo hits. Article

> Novo's Tresiba news injects uncertainty in insulin market, particularly for Sanofi. Story

Pharma Marketing News

> Next DTC push for Linzess: Spotlight patients, with big salesforce backup. More

> Pfizer, Merck KGaA suit up for Xalkori marketing wave. Report

> Does pricier mean better to ad consumers? FDA means to find out. Article

> Patient portals open door to lasting relationships with patients, 'Digital Doctor' says. Story

> Pfizer wants Canadians to think EpiPen. What else but a hockey partnership? More

Biotech Research News

> Zurich investigators ID pathway for B cell lymphoma. Item

> Berkeley, Harvard groups highlight new targets for cachexia. Report

> Regulus surges after AstraZeneca snags rights to NASH drug. More

> Whitehead team adapts CRISPR-Cas9 tech to target killer fungal infections. Article

> Daiichi Sankyo partners with Sanford-Burnham on a cardio molecule. Story

Diagnostics News

> Researchers develop paper microchip and smartphone diagnostic for HIV. Item

> OpGen eyes $35M IPO for drug-resistant bacteria tests. Story

> Roche and Foundation Medicine seal $1.2B deal with plans for cancer R&D. More

> Alere earns FDA clearance for rapid diagnostic of Strep A. News

> Natera ropes in $55M with eye on cancer Dx. Article

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.